Abstract: Compositions and methods are provided for the generation or treatment of chronic tympanic membrane perforation by modulation of HB-EGF activity.
Type:
Grant
Filed:
December 20, 2021
Date of Patent:
April 23, 2024
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Inventors:
Peter Luke Santa Maria, Yunzhi Yang, Sungwoo Kim, Chloe Domville-Lewis
Abstract: The invention provides isoform-selective anti-TGF? antibodies and methods of using the same. In particular, isoform-selective anti-TGF?2, anti-TGF?3, and anti-TGF?2/3 monoclonal antibodies are provided, e.g., for the treatment of fibrosis and other TGF?-related disorders.
Type:
Grant
Filed:
March 18, 2021
Date of Patent:
March 5, 2024
Assignee:
GENENTECH, INC.
Inventors:
Wei-Ching Liang, Joseph R. Arron, Daryle Depianto, Wendy Green Halpern, WeiYu Lin, Patrick J. Lupardus, Thirumalai Rajan Ramalingam, Dhaya Seshasayee, Tianhe Sun, Tulika Tyagi, Jia Wu, Yan Wu, Jian Ping Yin
Abstract: Peptides derived from NKp44 protein, chimeric peptides, nucleotides encoding same and pharmaceutical compositions comprising same, are provided. Further, methods of extending the biological half-life of a protein of interest are provided.
Type:
Grant
Filed:
October 11, 2021
Date of Patent:
February 27, 2024
Assignees:
THE NATIONAL INSTITUTE FOR BIOTECHNOLOGY IN THE NEGEV LTD., B. G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY
Inventors:
Ari-Angel Porgador, David Ben-Menahem, Roee Atlas
Abstract: The present invention provides multispecific antibodies that bind to EGFR and CD28 (EGFR×CD28) as well as anti-EGFR antibodies. Such antibodies may be combined with a further therapeutic agent such as an anti-PD1 antibody. Methods for treating cancers (e.g., EGFR-expressing cancer) by administering the antibodies (e.g., and combinations thereof with anti-PD1) are also provided. The EGFR×CD28 antibodies of the present invention embody a tumor-targeted immunotherapeutic modality combined with PD-1 inhibition. These bispecific antibodies bind a tumor-specific antigen (TSA) (EGFR) with one arm and the co-stimulatory receptor, CD28, on T-cells with the other arm. Combination therapy with PD-1 inhibitors specifically potentiated intra-tumoral T cell activation, promoting an effector memory-like T cell phenotype without systemic cytokine secretion in a variety of syngeneic and human tumor xenograft models.
Type:
Grant
Filed:
March 20, 2020
Date of Patent:
February 27, 2024
Assignee:
Regeneron Pharmaceuticals, Inc.
Inventors:
Dimitris Skokos, Andrew J. Murphy, George D. Yancopoulos, Chia-Yang Lin, Lauric Haber
Abstract: The present invention encompasses embodiments in which a therapeutic antibody is conjugated to ?-1,6-glucan oligomers. Thus, the present invention includes, among other things, compositions including a therapeutic antibody conjugated to one or more ?-1,6-glucan oligomers. The present invention further includes, among other things, methods of making and/or using such ?-1,6-glucan conjugates. In certain embodiments, a ?-1,6-glucan conjugate of the present invention is useful as a therapeutic or in a method of therapy.
Type:
Grant
Filed:
December 5, 2017
Date of Patent:
January 9, 2024
Assignee:
Innate Biotherapeutics, LLC
Inventors:
Gabriel Oscar Reznik, John James Kane, James Michael Siedlecki, Zuzana Dostalova, Isabelle Sansal-Castellano, Ifat Rubin-Bejerano, Hua Miao, Eric Steven Furfine
Abstract: The present invention relates to anti-VEGF/anti-IL-1beta antibodies and methods of using the same.
Type:
Grant
Filed:
September 8, 2021
Date of Patent:
January 9, 2024
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Roland Beckmann, Joerg Benz, Stefan Dengl, Christian Gassner, Guido Hartmann, Peter Michael Huelsmann, Sabine Imhof-Jung, Kristian Hobolt Jensen, Hubert Kettenberger, Stefan Lorenz, Joerg Moelleken, Olaf Mundigl
Abstract: The invention relates to polypeptides, in particular polypeptides comprising an immunoglobulin domain, binding to human Programmed Death Ligand-1 (huPDL1) and to applications of such polypeptides such as for use as a medicament or for use as diagnostic agent, for example as an immunotracer.
Type:
Grant
Filed:
March 1, 2019
Date of Patent:
January 2, 2024
Assignee:
VRIJE UNIVERSITEIT BRUSSEL
Inventors:
Jo Van Ginderachter, Geert Raes, Nick Devoogdt, Marleen Keyaerts, Quentin Lecocq, Catarina Xavier, Karine Breckpot, Katrijn Broos, Jessica Bridoux
Abstract: The present invention relates to Relaxin fusion polypeptides, in particular to Relaxin 2 fusion polypeptides and uses thereof. Thus, the invention provides Relaxin fusion polypeptides, nucleic acid molecules, vectors, host cells, pharmaceutical compositions and kits comprising the same and uses of the same including methods of treatment. The polypeptides and compositions of the invention may be useful, in particular, in the treatment of cardiovascular diseases, for example for the treatment of heart failure.
Type:
Grant
Filed:
November 17, 2021
Date of Patent:
December 19, 2023
Assignee:
MEDIMMUNE LIMITED
Inventors:
Weidong Hao, Andrew Garcia, Changshou Gao, Isabelle Sermadiras
Abstract: The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making the anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6.
Type:
Grant
Filed:
November 11, 2020
Date of Patent:
November 28, 2023
Assignee:
Vitaeris Inc.
Inventors:
Leon F. Garcia-Martinez, Anne Elisabeth Carvalho Jensen, Katie Anderson, Benjamin H. Dutzar, Ethan W. Ojala, Brian R. Kovacevich, John A. Latham, Jeffrey T. L. Smith
Abstract: Antibodies and compositions of matter useful for the detection, diagnosis and treatment of Hepatitis B Virus infection in mammals, and to methods of using those compositions of matter for the same.
Type:
Grant
Filed:
July 19, 2018
Date of Patent:
November 28, 2023
Assignee:
THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES
Inventors:
Paul T. Wingfield, Norman R. Watts, Alasdair C Steven
Abstract: The invention relates to PD-1 binding agents that do not block the interaction of PD-1 with its ligands, and the use of such binding agents in the treatment, prevention and detection of disease.
Type:
Grant
Filed:
January 8, 2018
Date of Patent:
November 14, 2023
Assignee:
CRESCENDO BIOLOGICS LIMITED
Inventors:
Bryan Edwards, Carolyn Edwards, James Legg, Martyna Lewandowska, Daniela Sydoruk, Colette Johnston, Christine Rossant, Yumin Teng
Abstract: The present invention relates to monoclonal antibodies and antigen-binding fragments thereof that bind to human ?-klotho, and pharmaceutical compositions and methods of treatment comprising the same.
Type:
Grant
Filed:
December 1, 2021
Date of Patent:
October 31, 2023
Assignee:
Novartis AG
Inventors:
Brian Boettcher, Shari Lynn Caplan, Regis Cebe, Guochun Li, John A. Taraszka, Fangmin Xu, David Langdon Yowe
Abstract: The present disclosure provides anti-EGFR antibody polypeptides, polynucleotides encoding the same, pharmaceutical compositions comprising the same, and the uses thereof.
Abstract: This application discloses ophthalmic formulations and methods for treating and preventing corneal haze and scarring with an hepatocyte growth factor (HGF) agent.
Type:
Grant
Filed:
April 20, 2021
Date of Patent:
September 19, 2023
Assignee:
The Schepens Eye Research Institute, Inc.
Abstract: The invention provides interleukin-33 (IL-33) antibodies and methods of making and using the same, e.g., for treatment of IL-33 mediated disorders (e.g., ocular disorders such as AMD (e.g., geographic atrophy (GA)).
Type:
Grant
Filed:
March 12, 2021
Date of Patent:
September 19, 2023
Assignee:
Genentech, Inc.
Inventors:
Gerald R. Nakamura, Dhaya Seshasayee, Menno Van Lookeren Campagne, Tiffany Wong, Jia Wu, Hongkang Xi, Jack Bevers, III, Hiu Nam Chan, Laetitia Comps-Agrar, Racquel Corpuz
Abstract: Provided herein are polypeptides that bind to a blood-brain barrier (BBB) receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a BBB receptor-expressing cell, e.g., for transport across the BBB. Also provided herein are transferrin receptor (TfR) constructs that comprise a monomeric TfR apical domain or one or more portions of the TfR apical domain which have been circularly permuted relative to the full-length TfR sequence.
Type:
Grant
Filed:
September 17, 2019
Date of Patent:
August 22, 2023
Assignee:
Denali Therapeutics Inc.
Inventors:
Xiaocheng Chen, Mihalis Kariolis, Robert C. Wells
Abstract: The present invention relates to anti-VEGF-A/anti-ANG2 antibodies, e.g. in the form of a bispecific Fab fragment, and methods of using the same.
Type:
Grant
Filed:
September 3, 2021
Date of Patent:
August 22, 2023
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Roland Beckmann, Sebastian Fenn, Guido Hartmann, Sabine Imhof-Jung, Kristian Hobolt-Jensen, Joerg Moelleken, Michael Molhoj, Christian Schantz, Janina Speck, Christoph Ullmer, Barbara Weiser
Abstract: Provided are constructs comprising a single-domain antibody (sdAb) moiety that specifically recognizes PD-1. Also provided are methods of making and using these constructs.
Type:
Grant
Filed:
January 15, 2019
Date of Patent:
August 1, 2023
Assignee:
Nanjing Legend Biotech Co., Ltd.
Inventors:
Yafeng Zhang, Shu Wu, Shuai Yang, Chuan-Chu Chou
Abstract: VH domain, in which: (i) the amino acid residue at position 112 is one of K or Q; and/or (ii) the amino acid residue at position 89 is T; and/or (iii) the amino acid residue at position 89 is L and the amino acid residue at position 110 is one of K or Q; and (iv) in each of cases (i) to (iii), the amino acid at position 11 is preferably V; and in which said VH domain contains a C-terminal extension (X)n, in which n is 1 to 10, preferably 1 to 5, such as 1, 2, 3, 4 or 5 (and preferably 1 or 2, such as 1); and each X is an (preferably naturally occurring) amino acid residue that is independently chosen, and preferably independently chosen from the group consisting of alanine (A), glycine (G), valine (V), leucine (L) or isoleucine (I).
Abstract: The present disclosure relates to monoclonal antibodies and antigen-binding fragments thereof that bind to human ?-klotho, and pharmaceutical compositions and methods of treatment comprising the same.
Type:
Grant
Filed:
December 18, 2020
Date of Patent:
July 4, 2023
Assignee:
Novartis AG
Inventors:
Regis Cebe, Stephane Olland, David Langdon Yowe